Altimmune Inc (ALT)
5.77
-0.15
(-2.53%)
USD |
NASDAQ |
Jun 18, 13:04
Altimmune Revenue (Annual): 0.426M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.426M |
| December 31, 2022 | -0.068M |
| December 31, 2021 | 4.41M |
| December 31, 2020 | 8.185M |
| December 31, 2019 | 5.801M |
| December 31, 2018 | 10.33M |
| December 31, 2017 | 10.74M |
| December 31, 2016 | 0.4101M |
| December 31, 2015 | 10.64M |
| December 31, 2014 | 10.19M |
| Date | Value |
|---|---|
| December 31, 2013 | 17.91M |
| December 31, 2012 | 25.18M |
| December 31, 2011 | 24.27M |
| December 31, 2010 | 20.99M |
| December 31, 2009 | 27.55M |
| December 31, 2008 | 32.91M |
| December 31, 2007 | 14.64M |
| December 31, 2006 | 1.663M |
| December 31, 2005 | 0.5861M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
-0.068M
Minimum
2022
8.185M
Maximum
2020
3.751M
Average
4.41M
Median
2021
Revenue (Annual) Benchmarks
| Eli Lilly and Co | 34.12B |
| Amgen Inc | 28.19B |
| Pfizer Inc | 58.50B |
| Viking Therapeutics Inc | -- |
| GlycoMimetics Inc | 0.01M |